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Abstract: Very rarely, patients with X-linked lymphoproliferative syn-
drome type 1 present central nervous system vasculitis. We report a patient 
carrying a SH2D1A mutation that, after treatment for lymphoma developed 
fatal central nervous system vasculitis. He lacked signs of ongoing Epstein–
Barr virus infection. We propose that impaired T cell homeostasis caused by 
SAP deficiency facilitates aberrant CD8+ T cell activation against vascular 
antigens promoting clinical manifestations.
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X-linked lymphoproliferative syndrome type 1 (XLP1) is a rare primary immunodeficiency with an estimated incidence of 2 
males/1.000.000 newborns.1 XLP1 is caused by hemizygous muta-
tions in SH2D1A, located at Xq25, that encodes the signaling lym-
phocytic activation molecule (SLAM)–associated protein (SAP).2 
SAP is a cytoplasmic protein expressed in NK and T cells. Upon 
recruitment to SLAM family receptors (e.g., 2B4), SAP promotes 
activating signaling. SAP deficiency renders SLAM receptors on 
lymphocytes inhibitory, resulting in impaired NK and CD8+ T 
cell cytotoxic responses toward SLAM family receptor-express-
ing hematopoietic target cells.2,3 Notably, CD8+ T cell cytotoxic 
responses in XLP1 are mostly preserved when antigens are pre-
sented by tissue cells as well as dendritic cells, but compromised in 
response to many hematopoietic cells, including B cells. Accord-
ingly, patients are particularly susceptible to Epstein–Barr virus 
(EPV), which establishes latency in B cells.4 During EBV infec-
tion, infected B cells upregulate expression of CD48 that binds 2B4 
expressed on T and NK cells. In XLP1 patients, impaired killing 
of EBV-infected cells may culminate in fulminant mononucleosis 
with excessive release of cytokines. Without treatment, a majority 
of the patients ultimately die.2,5
Another frequent presentation of XLP1 is hypo or dysgam-
maglobulinemia, secondary to defective interactions between B 
cells and follicular helper T cells.1,3 One fifth of XLP1 patients pre-
sent with lymphoma, while a minority of them present other mani-
festations such as aplastic anemia or vasculitis.1
We report an XLP1 patient who developed fatal central nerv-
ous system (CNS) vasculitis in the absence of active EBV-infection, 
6 months after completing treatment for Burkitt lymphoma.
MATERIALS AND METHODS
Flow Cytometry
For the evaluation of lymphocyte subsets, peripheral blood 
was analyzed by Flow Cytometry in a 4-color BD FACS Calibur 
(BD, San Jose, Calif.), using the BD IMK kit with Trucount tubes 
(BD Biosciences) according to the manufacturer’s instructions. An 
additional panel of monoclonal antibodies (including CD45RA, 
CD45RO, CD62L, and HLA-DR) was also performed for further 
characterization of T-cell differentiation, using a lyse-wash proto-
col. Finally, the IOTest Beta Mark kit (Immunotech SAS, a Beck-
man Coulter Company, Marseille, France) was also used for the 
characterization of the TCR Vβ repertoire.
Flow cytometry data analysis was performed using Multiset 
and CellQuestPro software (BD Biosciences).
Antibody Response Evaluation
Immunoglobulins were quantified in serum. Immunoturbi-
dimetria was used to quantify IgG, IgA and IgM. As for specific 
responses, antibodies for Diphtheria, Tetanus, and Pertussis were 
evaluated by enzyme-linked immunosorbent assay.
SAP Expression
Rested peripheral blood mononuclear cells (PBMCs) from 
the patient and controls were surface labeled for CD3 (OKT3), 
CD8 (SK1), CD19 (HIB19) and CD56 (NCAM16.2) before fixed 
in 4% paraformaldehyde and intracellularly stained for SAP (1C9, 
Abnova). Cells were acquired on an LSRFortssa (BD Bioscience) 
and analyzed with Flowjo 9.9.
Western Blot
Freshly isolated PBMCs were lysed in RIPA buffer (Santa 
Cruz Biotechnology) before protein content was quantified using a 
standard Bradford assay (ThermoFisher). Equal concentrations were 
run on a 12% Bis-Tris gel (Invitrogen) in the presence of 10 mM DTT. 
Anti-SAP (1C9) from Abnova and rat anti-SAP (1D12) from Cell 
Signaling Technology were used for immunoblotting. Mouse anti-
actin (C4) from MP Biomedicals was used as the loading control.
Polymerase Chain Reaction
One million PBMCs from a healthy control and the patient 
were harvested for generating cDNA (M-MLV, Invitrogen) following 
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manufacturer’s protocol. Taq polymerase (Invitrogen) was used for 
the polymerase chain reaction (PCR) reaction. Primers synthesized: 
β2-microglobulin forward 5’ AGTATGCCTGCCGTGTGAACC 
3’; β2-microglobulin reverse 5’ TGCGGCATCTTCAAACCTCCA 
3’; SH2D1A exon 1/2 5’ CCTATGTGTGCTGTATCACGG 3’; 
SH2D1A exon 3 5’ TGGCTTCTGAAATGCTGAAATG 3’.
RESULTS
A previously healthy 14-year-old boy presented with 
abdominal pain and loss of weight and was diagnosed with sporadic 
ileocaecal Burkitt lymphoma (Fig. 1A and fig., Supplemental Digi-
tal Content 1, http://links.lww.com/INF/D232). No evidence of 
ongoing EBV infection was found, as PCR for EBV in the blood was 
negative and serology provided evidence of past exposure (VCA-
IgM negative, VCA-IgG positive, negative EBNA). His brother 
had died of fulminant mononucleosis at 2 years of age, prompting 
further investigation. The patient manifested hypogammaglobu-
linemia, reduced class-switched memory B-cells, and lack of NKT 
cells (Table, Supplemental Digital Content 2, http://links.lww.
com/INF/D233). Moreover, SAP expression was absent, as meas-
ured by Western blot and flow cytometry in PBMCs (Fig. 1B, C). 
FIGURE 1. Pedigree and molecular diagnostics. A: Pedigree of the family including SH2D1A genotype. B: Analysis of SAP 
expression in PBMC lysates by Western blot in family members. C: Flow cytometric evaluation of SAP expression in NK and T cell 
subsets in controls and family members, as indicated. D: Sanger sequencing traces covering the patient SH2D1A mutation. E: 
PCR on PBMC-derived cDNA from a healthy control as well as the index patient using primers for SH2D1A and B2M, as indicated.
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Congruently, a hemizygous SH2D1A c.201G>A (p.E67E) synony-
mous mutation in exon 2 was identified (Fig. 1D), disrupting splic-
ing of exon 2 as evaluated by reverse transcription–PCR (Fig. 1E). 
The lack of exon 2 in SH2D1A mRNA results in a SAP protein 
lacking the crucial SH2 domain, as previously described by Debel-
jak et al.6
The patient was treated according to the mature B cell 
lymphoma 96 (LMB 96) protocol and achieved complete remis-
sion. The patient was proposed for hematopoietic stem cell trans-
plantation (HSCT), but 6 months after completing the lymphoma 
treatment, he presented with a short-term memory deficit. Mag-
netic resonance imaging revealed multiple infra and supratentorial 
edematous and hemorrhagic lesions with restricted diffusion (Fig., 
Supplemental Digital Content 3, http://links.lww.com/INF/D234).
Extensive investigation failed to identify any infectious 
agent. PCR on multiple samples (blood, stools, respiratory secre-
tions, cerebrospinal fluid [CSF], brain tissue) were negative for 
EBV, CMV, adenovirus, HHV6-8, enterovirus, HTLV, LCMV, HSV, 
VZV, parvovirus, JC and BK virus, arbovirus, bacterial 16s DNA, 
Rickettsia, Bartonella, Coxiella and Leptospira. Cultures from 
blood, stools, CSF, and brain biopsy were also negative. Examina-
tion of the Vβ T cell repertoire in peripheral blood did not detect 
any clonal expansions (data not shown). A cerebral stereotactic 
biopsy revealed signs of vasculitis, with perivascular invasion by 
CD8+ T lymphocytes, without B-cells (Fig., Supplemental Digital 
Content 4, http://links.lww.com/INF/D235). Epstein-Barr encoding 
region staining for EBV in this biopsy was negative.
The patient received broad-spectrum antibiotics and acyclo-
vir, as well as an aggressive treatment with intravenous immuno-
globulin, high-dose steroids, rituximab and intrathecal methotrexate 
and dexamethasone. Nonetheless, his mental and motor condition 
worsened. One month after the first symptoms, he was unable to 
walk, talk or recognize his parents. He received cyclophosphamide 
and alemtuzumab but continued to deteriorate. Finally, the patient 
became comatose. There was a notion of neurologic irreversibility, 
so the patient did not receive HSCT. He ultimately died 4 months 
after the first neurologic symptoms.
DISCUSSION
We report an XLP1 patient who presented Burkitt lym-
phoma followed by CNS vasculitis at 14 years of age. His brother, 
who died of fulminant infectious mononucleosis at 2 years of age, 
likely carried the same mutation. Specific SH2D1A mutations gen-
erally present with a spectrum of manifestations without predict-
able genotype-phenotype correlations.5
Malignant lymphomas are a well known manifestation of 
XLP1, being the initial manifestation of the disease in 14% of the 
patients.1 Most of the cases arise in extranodal sites, with Burkitt 
lymphoma of the ileocecal region being the most common presen-
tation.1,5,7 Remarkably, 20% of these patients are allegedly seron-
egative for EBV.2 A lack of correlation between EBV infection and 
lymphoma can be explained by the incapacity of the SAP-deficient 
CD8+ cells to respond to B-cells.2 Recent studies have determined 
that 3% of male patients with B-cell non Hodgkin lymphoma har-
bour a SH2D1A mutation.7
Central nervous system vasculitis is a very rare mani-
festation of XLP1. To our knowledge, there are only 8 previous 
patients with XLP1 manifesting central nervous system vasculitis 
(Table, Supplemental Digital Content 5, http://links.lww.com/INF/
D236).8–10 In the first descriptions, it was proposed that the vasculi-
tis was a complication of EBV infection of the cerebral vessel walls 
(as a result of defective viral clearance) or by aberrant activation 
of cytotoxic CD8+ T cells by EBV-infected B cells. However, in 
subsequent reports, most of the cases had no evidence of ongo-
ing EBV infection. The first 2 case reports to propose that CNS 
vasculitis could occur independent of active EBV infection did not 
perform PCR analysis of the CSF or brain tissue. In 2009, Talaat et 
al10 reported 2 patients with XLP1 that developed CNS vasculitis 
in the absence of ongoing EBV infection, substantiated by negative 
PCR in the affected tissues. We found EBV PCR repeatedly nega-
tive in the blood, CSF or brain tissue, as was Epstein-Barr encoding 
region in the brain tissue. Thus, our results substantiate the notion 
that severe manifestations of XLP1, including CNS vasculitis, may 
occur irrespective of EBV status.
Our report strengthens the idea that CNS vasculitis may 
occur irrespective of the EBV status of the recipient. The mech-
anisms that drive this fatal outcome in XLP1 patients remain 
obscure. Notably, reactivation-induced cell death is impaired in 
SAP-deficiency.2,5 Thus, we speculate that SAP-deficiency renders 
autoreactive T cells directed against vascular antigens resistant to 
apoptosis, potentially contributing to this rare clinical manifesta-
tion of XLP1.4,9
Notably, our patient is the fourth (4/9) reported to develop 
CNS vasculitis after completing chemotherapy for Burkitt lym-
phoma. Opportunistic infections could be responsible for promot-
ing aberrant immune responses, that is, CNS vasculitis. However, 
the fact that the abnormal cytotoxic responses in XLP1 are mostly 
related to antigens presented by B cells and that most pathogens are 
not restricted to these cells argues against this hypothesis. Moreo-
ver, we performed an extensive microbiologic investigation that 
was negative, which may rather suggest an aberrant response to 
endogenous ligands.
In summary, our report confirms that CNS vasculitis is a 
fatal manifestation of XLP1 that may occur in the absence of active 
EBV infection. Following diagnosis, HSCT should therefore be 
performed in a timely manner to avoid potentially fatal complica-
tions of the disease.
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